Weight-loss drugs avoid Wada banned list for 2027

Semaglutide, marketed under the Ozempic and Wegovy brands, was placed on Wada's monitoring database in 2024. Tirzepatide, known commercially as Mounjaro, was added to the same list this year. For a substance to progress from the monitoring database to the prohibited list, it must satisfy at least two of three criteria: it can enhance athletic performance, it poses a health risk to athletes, or it violates the spirit of sport. Wada has initiated one study and is preparing a second to examine the drugs' effects under conditions that mimic high‑level exercise. "It's inactive going to instrumentality america a small spot of clip to cod each this information, due to the fact that they are highly controlled studies successful precise circumstantial conditions," said Rabin. "What we privation to spot is whether immoderate of the pharmacological interaction connected quality physiology that has been observed successful obese patients would besides hap successful non-obese, highly trained people." Rabin noted that any potential advantages could be counteracted by side effects such as nausea, fatigue and loss of muscle mass. "If you're an jock and you suffer musculus mass, that whitethorn beryllium precise counterproductive for what you're trying to achieve," helium said. "So each these elements amusement you that